RS50642B - Triazolopyridinylsulfanyl derivatives as p38 map kinase inhibitors - Google Patents

Triazolopyridinylsulfanyl derivatives as p38 map kinase inhibitors

Info

Publication number
RS50642B
RS50642B RSP-2008/0599A RSP20080599A RS50642B RS 50642 B RS50642 B RS 50642B RS P20080599 A RSP20080599 A RS P20080599A RS 50642 B RS50642 B RS 50642B
Authority
RS
Serbia
Prior art keywords
independently selected
optionally substituted
halo
alkyl
conr5r6
Prior art date
Application number
RSP-2008/0599A
Other languages
Serbian (sr)
Inventor
John Paul Mathias
David Simon Millan
Russell Andrew Lewthwaite
Christopher Phillips
Original Assignee
Pfizer Inc.
Pfizer Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Inc., Pfizer Limited filed Critical Pfizer Inc.
Priority claimed from PCT/IB2005/002574 external-priority patent/WO2006018718A2/en
Publication of RS50642B publication Critical patent/RS50642B/en

Links

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Jedinjenje formule (I), ili njegova farmaceutski prihvatljiva so i/ili solvat (uključujući hidrat);gdeR1 je CH3, SCH3, SCH2CH3, CH2CH3, H ili CH2SCH3; R1aje CH3 ili CH2CH3;R2 je heteroaril, heterociklil, aril, ili karbociklil; R3 je heteroaril, heterociklil, aril, carbociklil ili R7;R7je (C1-C6)alkil po izboru supstituisan jednim ili više supstituenata nezavisno odabranim od OH, halo, NR5R6, (C1-C8)alkoksi, -S(O)p(C1-C8)alkil, CO2H, CONR5R6, heteroaril, heterociklil, aril, karbociklil, ariloksi, karbocikliloksi, heteroariloksi i heterocikliloksi; pjeO, 1 ili 2;R5 i R6 su svaki nezavisno odabrani od H i (C1-C4)alkil, dati (C1-C4) alkil je po izboru supstituisan jednim ili više supstituenata nezavisno odabranim od OH i halo, ili R5 i R6, zajeno sa azotom za koji su vezani formiraju piperazinil, piperidinil, morfolinil ili pirolidinil grupu, dati piperazinil, piperidinil, morfolinil i pirolidinil je svaki po izboru supstitusan jednim ili više OH;"aril" označava fenil ili naftil, dati fenil ili naftil je po izboru supstituisan jednim ili više supstituenata nezavisno odabranih od halo, -CN, -CO2H, ON, CONR5R6, R7 i R8; R8 je odabran od (C1-C6)alkil, (C1-C6)alkoksi, -CO2(C1-C6)alkil, -S(O)p(C1-C6)alkil, -CO(C1-C6)alkil i (C3-C7)cikloalkil;svaki R5 je po izboru supstituisan jednim ili više supstituenata nezavisno odabranih od: (C1-C6)alkoksi po izboru supstituisan jednim ili više supstituenata nezavisno selected from OH, halo, CO2H, CONR5R6 i NR5R6.-S(O)p(C1-C6)alkil po izboru supstituisan jednom ili više supstituenata nezavisno odabranih od OH, halo, CO2H, CONR5R6 i NR5R6,OH,halo,NR5R6,CO2H,CONR5R6, iR9;R9 je heteroaril2, heterociklil2, aril2, karbociklil2, aril2oksi, carbociklil2oksi, heteroaril2oksi ili heterociklil2oksi;"aril2", označava fenil ili naftil, dati fenil ili naftil je po izboru supstituisan jednim ili višesupstituenata nezavisno odabranih od halo, -CN, CO2H, OH i CONR5R6;"karbociklil" označava mono ili bicikličan, zasićen ili delimično nezasićen prstenasti sistemkoji sadrži 3 do 10 atoma ugljenika u prstenu, po izboru supstituisan jednim ili višesupstituenata nezavisno odbranih od halo, -CN, -CO2H, OH, CONR5R6, R8 i R9."karbociklil2" označava mono ili bicikličan, zasićen ili delimično nezasićen prstenastisistem sa 3 do 10 atoma ugljenika u prstenu, po izboru supstituisan jednim ili višesupstituenata nezavisno odabrnaih od halo, -CN, -CO2H, OH i CONR5R6;svaki "heterociklil", i "heterociklil2" nezavisno, označava 3- do 10-članu, zasićenu ilidelimično nezaišećnu, mono ili bicikličnu grupu sa 1 do 4 heteroatoma u prstenu,nezavisno odabranih od N, O, i S,svaki "heteroaril", i svaki "heteroaril2", nezavisno, označava 5 do 10 članu, mono ili bicikličnu, aromatičnu grupu koja sadrži od 1 do A compound of formula (I), or a pharmaceutically acceptable salt and / or solvate thereof (including hydrate), wherein R1 is CH3, SCH3, SCH2CH3, CH2CH3, H or CH2SCH3; R 1 is CH 3 or CH 2 CH 3; R 2 is heteroaryl, heterocyclyl, aryl, or carbocyclyl; R3 is heteroaryl, heterocyclyl, aryl, carbocyclyl or R7; R7 is (C1-C6) alkyl optionally substituted by one or more substituents independently selected from OH, halo, NR5R6, (C1-C8) alkoxy, -S (O) p (C1 -C8) alkyl, CO2H, CONR5R6, heteroaryl, heterocyclyl, aryl, carbocyclyl, aryloxy, carbocyclyloxy, heteroaryloxy and heterocyclyloxy; p is 0, 1 or 2; R 5 and R 6 are each independently selected from H and (C 1 -C 4) alkyl, the given (C 1 -C 4) alkyl is optionally substituted by one or more substituents independently selected from OH and halo, or R 5 and R 6. together with the nitrogen to which they are attached form a piperazinyl, piperidinyl, morpholinyl or pyrrolidinyl group, the piperazinyl, piperidinyl, morpholinyl and pyrrolidinyl each optionally substituted by one or more OH; "aryl" means phenyl or naphthyl, the phenyl or naphthyl optionally substituted by one or more substituents independently selected from halo, -CN, -CO2H, ON, CONR5R6, R7 and R8; R8 is selected from (C1-C6) alkyl, (C1-C6) alkoxy, -CO2 (C1-C6) alkyl, -S (O) p (C1-C6) alkyl, -CO (C1-C6) alkyl and ( C3-C7 cycloalkyl; each R5 is optionally substituted by one or more substituents independently selected from: (C1-C6) alkoxy optionally substituted by one or more substituents independently selected from OH, halo, CO2H, CONR5R6 and NR5R6.-S (O ) p (C1-C6) alkyl optionally substituted by one or more substituents independently selected from OH, halo, CO2H, CONR5R6 and NR5R6, OH, halo, NR5R6, CO2H, CONR5R6, iR9; R9 is heteroaryl2, heterocyclyl2, aryl2, carbocyclyl "aryl2", denotes phenyl or naphthyl, the phenyl or naphthyl optionally substituted by one or more substituents independently selected from halo, -CN, CO2H, OH and CONR5R6; "carbocyclic, or" carbocyclic, or "carbocyclic"; saturated or partially unsaturated ring systems containing from 3 to 10 carbon atoms in the ring, optionally substituted by one or more substituents independently selected from of halo, -CN, -CO2H, OH, CONR5R6, R8 and R9. "carbocyclyl2" means a mono or bicyclic, saturated or partially unsaturated ring system with 3 to 10 carbon atoms in the ring optionally substituted by one or more substituents independently selected from halo , -CN, -CO2H, OH and CONR5R6; each "heterocyclyl", and "heterocyclyl2" independently, denotes a 3- to 10-membered, saturated ilidelimically unsaturated, mono or bicyclic group with 1 to 4 ring heteroatoms independently selected from N , O, and S, each "heteroaryl", and each "heteroaryl2" independently denotes a 5 to 10 member, mono or bicyclic, aromatic group containing from 1 to

RSP-2008/0599A 2004-08-12 2005-08-09 Triazolopyridinylsulfanyl derivatives as p38 map kinase inhibitors RS50642B (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0418015A GB0418015D0 (en) 2004-08-12 2004-08-12 New compounds
US69155905P 2005-06-17 2005-06-17
PCT/IB2005/002574 WO2006018718A2 (en) 2004-08-12 2005-08-09 Triazolopyridinylsulfanyl derivatives as p38 map kinase inhibitors

Publications (1)

Publication Number Publication Date
RS50642B true RS50642B (en) 2010-06-30

Family

ID=33017410

Family Applications (1)

Application Number Title Priority Date Filing Date
RSP-2008/0599A RS50642B (en) 2004-08-12 2005-08-09 Triazolopyridinylsulfanyl derivatives as p38 map kinase inhibitors

Country Status (9)

Country Link
CN (1) CN101006087B (en)
GB (1) GB0418015D0 (en)
ME (1) ME01360B (en)
NI (1) NI200700039A (en)
PE (1) PE20060618A1 (en)
RS (1) RS50642B (en)
TW (1) TWI295926B (en)
UA (1) UA93032C2 (en)
ZA (1) ZA200700923B (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101422318B1 (en) * 2008-02-04 2014-07-22 화이자 리미티드 Polymorphic form of a [1,2,4]triazolo[4,3-a]pyridine derivative for treating inflammatory diseases
BRPI1005327A2 (en) * 2009-02-17 2019-09-24 Chiesi Farm Spa triazolopyridine derivatives as p38 map kinase inhibitors
GB201009731D0 (en) * 2010-06-10 2010-07-21 Pulmagen Therapeutics Inflamma Kinase inhibitors
ES2612259T3 (en) * 2011-12-09 2017-05-16 Chiesi Farmaceutici S.P.A. Kinase inhibitors
CN105693716A (en) * 2016-03-01 2016-06-22 孙霖 Crystal form A and preparing method
CN105646484A (en) * 2016-03-01 2016-06-08 孙霖 Crystal form B and preparation method

Also Published As

Publication number Publication date
CN101006087A (en) 2007-07-25
PE20060618A1 (en) 2006-07-14
CN101006087B (en) 2010-09-29
TW200610529A (en) 2006-04-01
ME01360B (en) 2010-06-30
TWI295926B (en) 2008-04-21
UA93032C2 (en) 2011-01-10
GB0418015D0 (en) 2004-09-15
ZA200700923B (en) 2008-09-25
NI200700039A (en) 2008-03-07

Similar Documents

Publication Publication Date Title
HRP20080608T3 (en) Triazolopyridinylsulfanyl derivatives as p38 map kinase inhibitors
RS52166B (en) Amino-heterocyclic compounds
AR060316A1 (en) UTILITY AZAINDOLS AS INHIBITORS OF JANUS QUINASAS
RS50642B (en) Triazolopyridinylsulfanyl derivatives as p38 map kinase inhibitors
CY1110232T1 (en) 2-Aryl-6-phenyl-imidazo [1,2-A] Pyridine derivative, their preparation and their application in therapeutic treatment
MX344276B (en) Novel piperidine compound or salt thereof.
NO20061456L (en) Use of CRTH2 antagonist compounds in therapy
HRP20080477T3 (en) Aryl-pyridine derivatives as 11-beta-hsd1 inhibitors
MY189118A (en) Pyrazolo[1,5-a]pyrazin-4-yl derivatives
RS53342B (en) Thieno-pyridine derivatives as mek inhibitors
WO2005070910A3 (en) Derivatives of 1-piperazine- and 1-homopiperazine-carboxylates, preparation method thereof and use of same as inhibitors of the faah enzyme
ATE442356T1 (en) 1-ACETIC ACID INDOL DERIVATIVES WITH PGD2 ANTAGONISTIC EFFECT
RS52702B (en) Carbazole compounds and therapeutic uses of the compounds
AR091022A1 (en) NAMPT INHIBITORS
HRP20020317B1 (en) Pharmaceutically active compounds
HRP20080311T3 (en) Pyrazole derivatives, compositions containing such compounds and methods of use
AR067599A1 (en) DERIVATIVES OF INDAZOL REPLACED ASSETS AS QUINASA INHIBITORS
RS52964B (en) 7-piperidinoalkyl-3,4-dihydroquinolone derivative
AR096450A1 (en) COMPOUNDS FOR THE MODULATION OF KINASES, AND ITS INDICATIONS
RS53588B1 (en) Compounds and compositions as protein kinase inhibitors
ATE556058T1 (en) 1-(2H)-ISOCHINOLOONE DERIVATIVE
HRP20050682B1 (en) Pyrazolopyridine derivatives
AR093504A1 (en) 4- (ORTO) -FLUOROPHENIL-5-FLUOROPIRIMIDIN-2-ILAMINES CONTAINING A SULFOXIMINE GROUP AS INHIBITORS OF CDK9, AN INTERMEDIARY FOR THEIR SYNTHESIS AND METHODS OF OBTAINING BOTH COMPOUNDS
RS52326B (en) Phenyl-piperazine derivatives as serotonin reuptake inhibitors
CO5550450A2 (en) DERIVATIVES OF 1-ACIL-PIRROLIDINE FOR THE TREATMENT OF VIRAL INFECTIONS